Volume 22, Number 12—December 2016
CME ACTIVITY - Research
Electrolyte and Metabolic Disturbances in Ebola Patients during a Clinical Trial, Guinea, 2015
Views: Views equals page views plus PDF downloadsMetric Details
Highlight and copy the desired format.
|EID||van Griensven J, Bah E, Haba N, Delamou A, Camara B, Olivier K, et al. Electrolyte and Metabolic Disturbances in Ebola Patients during a Clinical Trial, Guinea, 2015. Emerg Infect Dis. 2016;22(12):2120-2127. https://dx.doi.org/10.3201/eid2212.161136|
|AMA||van Griensven J, Bah E, Haba N, et al. Electrolyte and Metabolic Disturbances in Ebola Patients during a Clinical Trial, Guinea, 2015. Emerging Infectious Diseases. 2016;22(12):2120-2127. doi:10.3201/eid2212.161136.|
|APA||van Griensven, J., Bah, E., Haba, N., Delamou, A., Camara, B., Olivier, K....De Weggheleire, A. (2016). Electrolyte and Metabolic Disturbances in Ebola Patients during a Clinical Trial, Guinea, 2015. Emerging Infectious Diseases, 22(12), 2120-2127. https://dx.doi.org/10.3201/eid2212.161136.|
By using data from a 2015 clinical trial on Ebola convalescent-phase plasma in Guinea, we assessed the prevalence of electrolyte and metabolic abnormalities at admission and their predictive value to stratify patients into risk groups. Patients underwent testing with a point-of-care device. We used logistic regression to construct a prognostic model and summarized the predictive value with the area under the receiver operating curve. Abnormalities were common among patients, particularly hypokalemia, hypocalcemia, hyponatremia, raised creatinine, high anion gap, and anemia. Besides age and PCR cycle threshold value, renal dysfunction, low calcium levels, and low hemoglobin levels were independently associated with increased risk for death. A prognostic model using all 5 factors was highly discriminatory (area under the receiver operating curve 0.95; 95% CI 0.90–0.99) and enabled the definition of risk criteria to guide targeted care. Most patients had a very low (<5%) or very high (>80%) risk for death.
During the 2014–2016 Ebola virus disease (EVD) outbreak in West Africa, a total of 28,646 cases were diagnosed, with a case-fatality rate of 39.4% (1). Several research groups have focused on new therapeutic interventions, but none has been found to be very effective (2–4). Others have emphasized the importance of good supportive care (5–11). Besides indicating appropriate oral and intravenous hydration, a body of research has also made the case for increasing access to point-of-care (POC) devices to detect metabolic and electrolyte abnormalities (5–8,10–13) because pronounced abnormalities have been observed in Ebola virus patients treated in the United States and Europe (14).
However, the evidence base for this recommendation in busy, resource-limited Ebola treatment units (ETUs) remains limited. If few readily treatable electrolyte disturbances would be detected with these devices, their added value could be questioned because each blood collection puts healthcare workers at risk for infection (15). The limited understanding of the prognostic importance of these abnormalities further obscures the evidence base on their clinical value in resource-constrained settings. Moreover, findings might differ within and between countries, and information from various settings is thus required to inform management guidelines. Despite the ≈30,000 EVD cases diagnosed worldwide over the past 40 years, the evidence base on the prevalence and prognostic value of blood abnormalities is limited to a small number of reports on a fraction of all treated Ebola patients (4,16,17), many of whom were being treated intensively in high-resource settings (14,18,19).
A better understanding of abnormal blood test results could have important clinical consequences. First, more precise information on the prevalence of abnormalities could enable rational decision-making on which testing to prioritize and which abnormalities treatment programs should prepare to appropriately manage. Identified abnormalities could lead to relevant, simple therapeutic interventions (e.g., potassium [K+] supplementation) that could reduce case-fatality rates. Second, identification of factors independently associated with an increased risk for death could lead to better prognostic classification of patients, identifying those in need of higher levels of care, and improve standardization when analyzing results of future clinical trials. To enable clinical decision-making, estimates of the absolute risk for death would be required for individual patients across the spectrum of independent risk factor values (20) and not the mere reporting of group odds or risk ratios, as has been done before (16,17). Based on the predicted absolute risk for death, individual risk stratification could be done on admission.
The Ebola-Tx trial evaluated convalescent-phase plasma as an EVD treatment in a Médecins sans Frontières (MSF) ETU in Conakry, Guinea. Trial findings have been published (2). MSF introduced a POC device during the trial. We used the opportunity of having access to relatively high-quality data from this clinical trial to 1) describe the prevalence of electrolyte and metabolic disturbances during admission and the association with EVD death and 2) assess the predictive value of these prognostic factors to stratify patients in risk groups.
The Ebola-Tx trial was conducted at the Conakry ETU supported by MSF. Trial patients were recruited during February 17–July 7, 2015. Patients of all ages, including pregnant women, were eligible, and their outcomes were compared with historical controls treated at the same center before the trial began. As per World Health Organization recommendations, patients received 2 units of 200–250 mL of Ebola convalescent-phase plasma after EVD diagnosis was confirmed by PCR (2). For children, a total volume of 10 mL/kg of Ebola convalescent-phase plasma was given. The level of neutralizing antibodies in the donors was unknown at the time of administration. Although the trial was found safe and feasible to organize, the efficacy of convalescent-phase plasma was not proven; the adjusted absolute risk reduction was −3% (95% CI −13% to 8%) (2).
Supportive Care at the MSF ETU
Supportive care during the trial was provided by the MSF team as per MSF guidelines. As part of supportive care, MSF staff introduced a POC device (i-STAT; Abbott Point of Care, Princeton, NJ, USA) on February 25, 2015, soon after the trial began. All patients were tested at the time of EVD diagnosis by using CHEM8+ cartridges (Abbott Point of Care) to determine levels of electrolytes (K+, sodium [Na+], chloride [Cl–], and ionized calcium [iCa2+]), creatinine, and blood urea nitrogen (BUN); the anion gap; the total amount of dissolved carbon dioxide (TCO2); glucose levels; and hemoglobin/hematocrit values.
The MSF supportive care guidelines recommend empirical systematic prescription of antibiotics and antimalarial drugs. Symptomatic care (e.g., for pain or nausea/vomiting) was given as needed. Fluid replenishment was done with oral rehydration fluids if a patient was alert, not vomiting, and able to participate in their own care. Intravenous fluids were given to patients with insufficient oral intake, severe vomiting or diarrhea, pronounced or persistent hypotension, or clinical signs of severe dehydration (21).
A total of 102 patients were enrolled in the Ebola-Tx trial, of whom 98 received convalescent-phase plasma. A total of 87 were recruited after the introduction of the POC device.
During the trial, data were entered in an electronic case report form directly from source documents, which, when filled in the high-risk zone, were scanned using mobile phones and transmitted over a secured local wireless network to a central server and automated printer. Data were collected on admission and each day after EVD confirmation, including information on symptoms and clinical signs of EVD, vital signs, and treatment received. For our study, we used all available data on the POC results on admission, cycle threshold (Ct) values of the Ebola diagnostic PCR, baseline patient characteristics, and discharge status.
We used definitions based on the POC device normal values and standard definitions for abnormalities: hypokalemia, K+ <3.5 mmol/L; moderate hypokalemia, K+ 2.5–3.0 mmol/L; severe hypokalemia, K+ <2.5 mmol/L; hyperkalemia, K+ >5.0 mmol/L; hyponatremia, Na+ <135 mmol/L; hypernatremia, Na+ >146 mmol/L; hypochloremia, Cl– <98; high anion gap, >20; low TCO2, <24 mmol/L; low glucose, <70 mg/dL; high glucose >180 mg/dL; creatinine and BUN: mild increase, 1.0–1.5 times the upper limit of normal (ULN); moderate increase, 1.5–3.0 times ULN; severe, >3.0 times ULN; increased BUN/creatinine ratio, >20; and hypocalcemia, iCa2+ <1.12 mmol/L. Anemia was defined per World Health Organization guidelines (age/sex adjusted) using hemoglobin values (22).
We calculated medians and interquartile ranges (IQRs) for continuous variables and summarized binary/categorical data by using frequencies and percentages. We compared groups by using Fisher exact tests for binary/categorical variables and the Wilcoxon rank-sum test for continuous variables.
The outcome status at the time of discharge from the MSF ETU was classified as alive or dead, excluding patients transferred to another ETU. We performed a risk factor analysis by using multivariate logistic regression modeling to determine independent factors associated with increased risk for death. We selected a restricted number of exposure variables on the basis of theoretical considerations and published studies. We included the following variables in the POC model: K+, iCa2+, and creatinine levels; anion gap; amount of TCO2; glucose levels; and hemoglobin levels. The POC+ model included the same POC variables plus age and the Ct of the PCR at EVD diagnosis, given that these 2 additional variables are the most universally accepted prognostic factors (4,23,24). To maximize power, we included the variables as continuous variables and determined the functional form by using the fracpoly command (fractional polynomial regression, which fits fractional polynomials as part of the specific regression model) in Stata version 14 (StataCorp LP, College Station, TX, USA). We reduced the model by using backward stepwise elimination until all variables had a p value <0.05. By using the logistic regression coefficients from the final model, we calculated the predicted risk for death for each patient and plotted the results in a histogram. We summarized the predictive value of the model by calculating the area under the receiver operating curve (AUROC) separately for the POC and the POC+ model.
We tabulated predicted and observed deaths across different predicted risk groups (<5.0%, 5.0%–19.9%, 20.0%–49.9%, 50.0%–79.9%, and >80.0%). We formally assessed the goodness-of-fit of the model by using the Hosmer-Lemeshow test, yielding a p value <0.05, which suggests significant discrepancy between the observed and predictive outcomes. We conducted internal validation by using cross-validation (h = 10, k = 10) (25). We randomly divided the data into 10 mutually exclusive subsets of the same size. We conducted a 10-fold cross-validation by repeating the analysis 10 times, each time excluding 1 of the independent datasets, and calculating the AUROC. We averaged the summary estimates of the 10 AUROCs to obtain the cross-validation AUROC. We conducted statistical analysis by using Stata version 14.
Of the 87 study patients enrolled in the trial when the POC device was in use, POC results were available for 85 (Table 1). The median age was 30 years (IQR 20–40 years); 48 (56%) patients were female. The median Ct value in the diagnostic PCR was 27 (IQR 18–36).
Hyponatremia (77.6%) was very common, but hypernatremia was only rarely documented (Table 2). Although hypokalemia (33%) was common, severe hypokalemia (K+ <2.5 mmol/L) and hyperkalemia were rare. Hypocalcemia (64%) was frequently observed. Renal dysfunction (45% with increased creatinine levels), an increased anion gap (28%), and decreased TCO2 (71%) all were frequently documented. Anemia was observed in 27% of patients.
In the multivariate logistic regression modeling, decreased iCa+ and hemoglobin levels and increased creatinine levels were associated with increased risk for death (POC model). In the POC+ model, age and the diagnostic PCR Ct value were additionally selected (Table 3). A prediction model based on these 5 factors provided estimates of the risk for death ranging from 0.016% to 99.99%, compared with a baseline (or pretest) risk for death of 34.6% (27/78 patients). The largest risk groups were patients at either very low or very high risk, with 40% of patients having a risk for death <10% and 22% having a risk >80% (Figure 1). This POC+ model had an AUROC of 0.95 (95% CI 0.90–0.99), compared with 0.88 (95% CI 0.78–0.97) for the model that only included creatinine, calcium, and hemoglobin levels (POC model) (Figure 2). AUROC cross-validation values were 0.92 (95% CI 0.85–0.99) for the POC+ model and 0.85 (95% CI 0.75–0.96) for the POC model. The Hosmer-Lemeshow test yielded a p value of 0.98 for the POC+ model and 0.34 for the term POC model. The predicted and observed risk for death was stratified into 5 risk groups (Table 4); most patients were in the <5% or >80% risk group categories.
We documented a high prevalence of multiple electrolyte and metabolic abnormalities in Ebola patients at the time of admission during a clinical trial of convalescent-phase plasma in Guinea. Increased creatinine and decreased calcium and hemoglobin levels during admission were independent risk factors for death. The POC model including these factors and the POC+ model additionally including 2 key risk factors (Ct value of the diagnostic Ebola PCR and the age of the patient) both performed well in predicting individual patient outcome. The predicted risk for death ranged from <0.02% to 99.9%, and most patients were found to have either a very low risk (<5%) or a very high risk (>80%) for death.
The frequent observance of electrolyte disturbances is in line with the few available studies from Africa (17,26). The high prevalence of hypokalemia is of particular interest, although it was rarely severe at the time of admission. Nevertheless, hypokalemia can potentially be fatal and is amenable to relatively simple interventions. A deficiency in iCa+ was common, a finding also frequently observed in sepsis patients (27,28). In the case of EVD, renal dysfunction and pancreatitis also could contribute. The high anion gap and low TCO2 are likely explained by lactic acidosis. Renal failure was also common in our study. The exact cause of renal dysfunction in EVD patients remains undefined, but both prerenal and renal causes probably are involved.
The POC+ model, a 5-measure prognostic tool, enabled the stratification of patients into different risk groups at baseline, with risk for death ranging from <5% to >80%. This tool could enable the refining of clinical care pathways and rational use of scarce human resources. Absolute risks for death could easily be calculated via a spreadsheet or smartphone application. Alternatively, scoring systems could be developed for bedside use (29,30).
However, several issues need to be addressed before such prognostic tools are taken forward. First, we did not include other potentially relevant measures that can be tested with POC devices, such as liver function tests, coagulation abnormalities, or markers of inflammation. Although our system performed fairly well with only a few markers, evaluation of the full panel of tests could possibly lead to further improvement. Second, the sample size in our study was limited, and all but 2 of the patients received convalescent-phase plasma. Although transfusion of 500 mL of plasma probably will not strongly influence the prognostic associations, larger studies in different study populations are required to assess the generalizability of our findings. Third, corrective measures for some abnormalities (e.g., hypoglycemia or hypokalemia) could have obscured associations with survival. Moreover, because this was an exploratory study, our findings need to be validated in other and larger datasets. Finally, it remains to be seen whether (and if so how much) our prognostic tool would perform substantially better than clinical judgement alone or a prognostic tool relying on clinical signs/symptoms combined with age and the PCR Ct value. Nevertheless, a prognostic clinical tool using laboratory measures will have the advantage of being more objective, less variable between clinicians, and less dependent on specific clinical skills.
In contrast to fixed variables such as age and the PCR Ct value that are only useful as prognostic markers, the detection of hypocalcemia, anemia, and renal dysfunction is amenable to interventions. If these conditions are causally associated with an increased risk for death, their detection could contribute to reducing case-fatality rates. If they are only a proxy for another causal factor, correction of these abnormalities might have minimal effects. For instance, surprisingly limited evidence exists that correction of hypocalcemia in intensive care patients improves survival (27), and some evidence suggests that it could even be detrimental (28). Similarly, whether blood transfusion in cases of anemia can improve EVD survival (and at what threshold hemoglobin value) requires further study. Anemia has been found to be associated with an increased risk for death in other inflammatory conditions such as sepsis (31). However, subsequent studies demonstrated that a liberal blood transfusion strategy could have a negative impact on survival in intensive care patients (32).
The association of renal dysfunction with an increased risk for death has been demonstrated before (4,17,26,33). However, the added clinical value of being able to diagnose renal dysfunction, beyond its prognostic value, in the typical ETU in countries of Africa remains unclear. It could enable staff to more carefully assess the fluid status and thus avoid over- and under-hydration. However, renal dysfunction could be prerenal (requiring aggressive fluid administration) or renal (requiring more cautious fluid administration) in origin. Carefully assessing fluid status in busy ETUs with brief patient contact remains challenging, and to what extent the ratio of BUN to creatinine is accurate in EVD patients is unclear (17). Whether biochemical diagnosis (and management) of kidney dysfunction substantially improves patient outcomes compared with monitoring urine output and clinically assessing fluid status also remains unknown. It would be more useful to monitor for renal dysfunction if compensatory measures such as dialysis could be put in place (34). Clinical trials would be required to assess this further, looking at case-fatality rate reduction, risk to healthcare staff, and opportunity costs (9). As blood transfusion requires blood group testing and, ideally, bedside cross-matching, risk-benefit assessments for this intervention would also be useful to inform treatment guidelines.
We acknowledge that underestimation of the prevalence of abnormalities is probable because as measurements were not systematically performed during the entire stay in the ETU. Still, our findings show that a POC device is practical to use in the ETU and could be useful in stratifying patients into risk groups at baseline. Information on the extent POC results were used by the clinicians would also have strengthened the study.
In conclusion, in the challenging environment of an ETU, staff wearing full protective equipment were able to use a POC device that frequently detected metabolic and electrolyte abnormalities among EVD patients at admission. Besides age and diagnostic PCR Ct value, renal dysfunction, low calcium levels, and low hemoglobin levels were independently associated with an increased risk for death. A clinical prognostic model using these 5 factors had a high discriminatory potential, with most patients having either very low (<5%) or very high (>80%) risk for death. To what extent interventions aiming at correcting the observed abnormalities can reduce case-fatality rates remains to be assessed. Moreover, risk-benefit assessments that consider the risks to healthcare workers are required to inform treatment guidelines.
Dr. van Griensven acted as coordinating investigator of the Ebola-Tx trial and is currently leading the unit of HIV and Neglected Tropical Diseases at the Institute of Tropical Medicine in Antwerp, Belgium. His research interests include leishmaniasis and emerging infectious disease outbreaks.
The authors would like to thank the Ebola-Tx consortium and all those who have contributed to the implementation of the Ebola-Tx trial, including public health authorities, National Blood Transfusion Centre staff, Ebola treatment center staff, all Médecins sans Frontières staff, laboratory staff, communities, and Ebola survivors. Our gratitude goes to the Clinical Trials Unit of Institute of Tropical Medicine, which supported the implementation of the trial.
The Ebola-Tx project is funded by the European Union’s Horizon 2020 program for research and innovation under grant agreement no. 666094. Additional funding is provided by the Department of Economy, Science, and Innovation of the government of Belgium. The mobile plasma unit used in this trial was provided to Guinea by the Bill and Melinda Gates Foundation. M.G.S. is supported by a grant from the National Institute for Health Research Health Protection Research Unit in the Emerging and Zoonotic Infections Department at the University of Liverpool.
- World Health Organization. Ebola situation report—30 March 2016 [cited 2016 Jun 1]. http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march-2016
- van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al.; Ebola-Tx Consortium. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374:33–42.
- Dunning J, Sahr F, Rojek A, Gannon F, Carson G, Idriss B, et al.; RAPIDE-TKM trial team. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med. 2016;13:e1001997.
- Sissoko D, Laouenan C, Folkesson E, M’Lebing AB, Beavogui AH, Baize S, et al.; JIKI Study Group. Experimental treatment with favipiravir for Ebola Virus Disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13:e1001967.
- Fletcher TE, Fowler RA, Beeching NJ. Understanding organ dysfunction in Ebola virus disease. Intensive Care Med. 2014;40:1936–9.
- Fowler RA, Fletcher T, Fischer WA II, Lamontagne F, Jacob S, Brett-Major D, et al. Caring for critically ill patients with ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190:733–7.
- Lamontagne F, Clément C, Fletcher T, Jacob ST, Fischer WA II, Fowler RA. Doing today’s work superbly well—treating Ebola with current tools. N Engl J Med. 2014;371:1565–6.
- Wong KK, Perdue CL, Malia J, Kenney JL, Peng S, Gwathney JK, et al.; Monrovia Medical Unit. Supportive care of the first 2 Ebola virus disease patients at the Monrovia Medical Unit. Clin Infect Dis. 2015;61:e47–51.
- West TE, von Saint André-von Arnim A. Clinical presentation and management of severe Ebola virus disease. Ann Am Thorac Soc. 2014;11:1341–50.
- Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa—clinical manifestations and management. N Engl J Med. 2014;371:2054–7.
- Hunt L, Lee JS. Empiric intravenous fluid and electrolyte therapy in patients with Ebola virus disease. Trop Doct. 2016;46:148–50.
- Palich R, Gala JL, Petitjean F, Shepherd S, Peyrouset O, Abdoul BM, et al.; ALIMA N’zérékoré Ebola Treatment Center medical group. A 6-year-old child with severe Ebola virus disease: laboratory-guided clinical care in an Ebola treatment center in Guinea. PLoS Negl Trop Dis. 2016;10:e0004393.
- Clay KA, Johnston AM, Moore A, O’Shea MK. Targeted electrolyte replacement in patients with Ebola virus disease. Clin Infect Dis. 2015;61:1030–1.
- Uyeki TM, Mehta AK, Davey RT Jr, Liddell AM, Wolf T, Vetter P, et al.; Working Group of the U.S.–European Clinical Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016;374:636–46.
- Kok J, Sintchenko V, Dwyer DE, Chen SC. Editorial: Laboratory preparedness for Ebolavirus disease. [editorial]. Pathology. 2015;47:397–9.
- Hunt L, Knott V. Serious and common sequelae after Ebola virus infection. Lancet Infect Dis. 2016;16:270–1.
- Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196(Suppl 2):S364–71.
- Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, et al.; Emory Serious Communicable Diseases Unit. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371:2402–9.
- Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med. 2014;371:2394–401.
- Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al.; PROGRESS Group. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10:e1001381.
- Sterck A. Filovirus haemorrhagic fever guideline [cited 2016 Jun 1]. http://www.medbox.org/ebola-guidelines/filovirus-haemorrhagic-fever-guideline/preview
- World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva: The Organization; 2011.
- Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372:40–7.
- Faye O, Andronico A, Faye O, Salje H, Boëlle PY, Magassouba N, et al. Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study. PLoS Med. 2015;12:e1001908.
- Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.
- Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V, Tamba K, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015;15:1292–9.
- Forsythe RM, Wessel CB, Billiar TR, Angus DC, Rosengart MR. Parenteral calcium for intensive care unit patients. Cochrane Database Syst Rev. 2008;4:CD006163.
- Collage RD, Howell GM, Zhang X, Stripay JL, Lee JS, Angus DC, et al. Calcium supplementation during sepsis exacerbates organ failure and mortality via calcium/calmodulin-dependent protein kinase kinase signaling. Crit Care Med. 2013;41:e352–60.
- van Griensven J, Phirum L, Thai S, Buyze J, Lynen L. A clinical prediction score for targeted creatinine testing before initiating tenofovir-based antiretroviral treatment in Cambodia. J Acquir Immune Defic Syndr. 2014;65:e150–2.
- van Griensven J, Phan V, Thai S, Koole O, Lynen L. Simplified clinical prediction scores to target viral load testing in adults with suspected first line treatment failure in Phnom Penh, Cambodia. PLoS One. 2014;9:e87879.
- Hébert PC, Wells G, Tweeddale M, Martin C, Marshall J, Pham B, et al. Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group. Am J Respir Crit Care Med. 1997;155:1618–23.
- Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409–17.
- Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al.; KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092–100.
- Faubel S, Franch H, Vijayan A, Barron MA, Heung M, Liu KD, et al. Preparing for renal replacement therapy in patients with the Ebola virus disease. Blood Purif. 2014;38:276–85.
TablesCite This Article
- Page created: November 17, 2016
- Page last updated: November 17, 2016
- Page last reviewed: November 17, 2016
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)